A Multicenter, Open-Label Study to Evaluate the Safety and Tolerability of Intravenous Brivaracetam as Replacement for Oral Brivaracetam in Japanese Subjects ≥16 Years of Age With Partial Seizures With or Without Secondary Generalization
Phase of Trial: Phase III
Latest Information Update: 14 Oct 2019
Price : $35 *
At a glance
- Drugs Brivaracetam (Primary)
- Indications Epilepsy
- Focus Adverse reactions; Registrational
- Sponsors UCB Biopharma
- 09 Oct 2019 Planned End Date changed from 1 Jun 2020 to 1 Mar 2021.
- 09 Oct 2019 Planned primary completion date changed from 1 Jun 2020 to 1 Mar 2021.
- 04 Jan 2019 Status changed from not yet recruiting to recruiting.